Another manufacturer blocks drug for execution use (Update)

September 27, 2012 by Alan Scher Zagier

(AP)—A manufacturer of the anesthetic blamed for Michael Jackson's death said Thursday it won't sell propofol for use in U.S. executions, a setback for Missouri and other states looking for an alternative after other drug makers also objected to their products' use in lethal injections.

Drug maker Fresenius Kabi USA, a German company with U.S. offices based in Schaumburg, Illinois, is one of only two domestic suppliers of propofol, and is the only one currently distributing in the U.S. Earlier this year, Missouri adopted a new single-drug execution method that would make it the first state to use propofol on death-row inmates. Other states also have considered incorporating the drug into their lethal injections.

Fresenius Kabi spokesman Matt Kuhn confirmed to The Associated Press that the company told its distributors in late August that such usage is "inconsistent" with the company's mission. It's also forbidden under European Union laws to export drugs that could be used in executions.

"Fresenius Kabi objects to the use of its products in any manner that is not in full accordance with the medical indications for which they have been approved by health authorities," a company statement reads. "Consequently, the company does not accept orders for propofol from any departments of correction in the United States. Nor will it do so."

Most of the 33 U.S. states with the death penalty had long used sodium thiopental as the first of a three-drug combination administered during lethal injections. But that drug also became unavailable when its European supplier acknowledged pressure from death penalty opponents and stopped selling it for executions.

Supplies mostly ran out or expired, forcing states to consider alternatives. Most states have retained the three-drug method but turned to pentobarbital, a barbiturate used to treat anxiety and convulsive disorders such as epilepsy, as a replacement for sodium thiopental. Pentobarbital supplies also have shrunk after its manufacturer said it would try to prevent its use in executions.

A spokeswoman for the Missouri Attorney General's office declined comment Thursday, and Department of Corrections officials didn't respond to several requests seeking comment about Fresenius Kabi's decision. In August, the state Supreme Court declined Attorney General Chris Koster's request to set execution dates for six death-row inmates, calling it "premature" pending the uncertainty over propofol's availability.

Richard Dieter, executive director of the Washington-based Death Penalty Information Center, called the drug maker's decision the latest obstacle to a capital punishment procedure that until several years ago had been virtually unchanged for more than three decades.

"States have chosen a medical model. And in general, the medical profession is not involved in things other than life-preserving acts," he said. "It's going to be an ongoing problem. States might have to keep changing (drug protocols), or come up with a whole new (execution) method."

In an Aug. 28 letter to health care providers, a Fresenius Kabi USA executive vice president said the company will now "more tightly control access" by wholesalers and distributors to propofol, which is marketed by subsidiary APP under the brand name Diprivan. The drug will not be sold to retail pharmacies or third-party distributors "to reduce the possibility that propofol reaches correctional facilities," wrote Scott Meacham, also the company's chief commercial officer.

Hospira, the only other company that distributes propofol in the U.S., has exhausted its supply and doesn't expect to release the drug for further sale until at least October or November. The Lake Forest, Illinois-based company also has come out with strong opposition to the use of its products for capital punishment, which spokesman Dan Rosenberg reiterated Thursday. Rosenberg declined to comment about whether Hospira also would block the sale of the drug to corrections departments when the new supply is released.

The rate of executions in Missouri and the rest of the country has slowed considerably as the supply of lethal injection drugs dried up. The U.S. had 98 executions in 1999 but fewer than half that amount last year. Missouri executed 66 convicted killers between 1989—the year executions resumed in the state—and 2005, but only two inmates have been put to death since.

Missouri's proposed use of propofol also has come under scrutiny because the state's written execution protocol does not require a physician to be part of the execution team. Propofol typically is administered by an anesthesiologist or a nurse anesthetist under direct physician supervision.

Explore further: Missouri opts for untested drug for executions

shares

Related Stories

Missouri opts for untested drug for executions

May 24, 2012
(AP) -- The same anesthetic that caused the overdose death of pop star Michael Jackson is now the drug of choice for executions in Missouri, causing a stir among critics who question how the state can guarantee a drug untested ...

Docs facing questions about 'Michael Jackson drug'

October 20, 2011
(AP) -- Doctors sometimes call the anesthesia drug by its nickname - milk of amnesia. Patients are calling it the "Michael Jackson drug."

Recovery from propofol anesthesia may be sped by use of common stimulant

April 5, 2012
The ability of the commonly used stimulant methylphenidate (Ritalin) to speed recovery from general anesthesia appears to apply both to the inhaled gas isoflurane, as previously reported, and to the intravenous drug propofol. ...

Bristol-Myers recalls vials of cancer drug

August 30, 2012
(AP)—Bristol-Myers Squibb Co. is recalling more than 31,000 units of a chemotherapy drug after discovering one vial was overfilled, putting patients at risk of an overdose.

Recommended for you

Drug for spinal muscular atrophy prompts ethical dilemmas, bioethicists say

December 11, 2017
When the Food and Drug Administration approved the first drug for people with spinal muscular atrophy a year ago, clinicians finally had hope for improving the lives of patients with the rare debilitating muscular disease. ...

FDA's program to speed up drug approval shaved nearly a year off the process

December 7, 2017
Speeding the pace at which potentially lifesaving drugs are brought to market was a rallying cry for Donald Trump as a candidate, and is a stated priority of his Food and Drug Administration commissioner, Dr. Scott Gottlieb. ...

Dangers of commonly prescribed painkillers highlighted in study

December 6, 2017
Commonly prescribed painkillers need to be given for shorter periods of time to reduce the risk of obesity and sleep deprivation, a new study has revealed.

Viagra goes generic: Pfizer to launch own little white pill

December 6, 2017
The little blue pill that's helped millions of men in the bedroom is turning white. Drugmaker Pfizer is launching its own cheaper generic version of Viagra rather than lose most sales when the impotence pill gets its first ...

Surgery-related opioid doses can drop dramatically without affecting patients' pain

December 6, 2017
Some surgeons might be able to prescribe a third of opioid painkiller pills that they currently give patients, and not affect their level of post-surgery pain control, a new study suggests.

Four-fold jump in deaths in opioid-driven hospitalizations

December 4, 2017
People who end up in the hospital due to an opioid-related condition are four times more likely to die now than they were in 2000, according to research led by Harvard Medical School and published in the December issue of ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.